Gemzar Combo NSCLC Therapy Data Also Supports Monotherapy - FDA Cmte.
Executive Summary
Data from Lilly's Phase III studies of Gemzar combination regimens for non-small cell lung cancer helped convince members of FDA's Oncologic Drugs Advisory Committee to recommend it for single-agent palliative NSCLC therapy for approval March 19.